Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Receivables: 2011-2025

Historic Change in Receivables for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to $236,000.

  • Enanta Pharmaceuticals' Change in Receivables rose 5.16% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $236,000, marking a year-over-year increase of 111.99%. This contributed to the annual value of $236,000 for FY2025, which is 111.99% up from last year.
  • According to the latest figures from FY2025, Enanta Pharmaceuticals' Change in Receivables is $236,000, which was up 111.99% from -$2.0 million recorded in FY2024.
  • Enanta Pharmaceuticals' 5-year Change in Receivables high stood at $236,000 for FY2025, and its period low was -$11.7 million during FY2023.
  • For the 3-year period, Enanta Pharmaceuticals' Change in Receivables averaged around -$4.5 million, with its median value being -$2.0 million (2024).
  • Its Change in Receivables has fluctuated over the past 5 years, first tumbled by 3,978.57% in 2022, then spiked by 111.99% in 2025.
  • Yearly analysis of 5 years shows Enanta Pharmaceuticals' Change in Receivables stood at $84,000 in 2021, then plummeted by 3,978.57% to -$3.3 million in 2022, then plummeted by 259.24% to -$11.7 million in 2023, then spiked by 83.19% to -$2.0 million in 2024, then skyrocketed by 111.99% to $236,000 in 2025.